Inactive Instrument

VIVUS, Inc.

VVUSQ

US9285513084

VIVUS, Inc. Announces Appointment of Ken Suh as President

August 06, 2018 at 05:00 pm IST

VIVUS, Inc. (the “Company”) announced the appointment of Ken Suh to the position of President. Previously, Mr. Suh was President and CEO of Willow Biopharma Inc. As President of VIVUS, Mr. Suh will work to advance the Company toward its core objectives of product portfolio optimization and enterprise value creation. Mr. Suh founded Willow Biopharma Inc., in 2015 and served as President and Chief Executive Officer.

Latest news about VIVUS, Inc.

Vivus, Inc. Announces the Publication of New Clinical Trial Data Demonstrating That Pancreaze Helped to Stabilize Weight in Patients Undergoing Chemotherapy for the Treatment of Pancreatic Ductal Adenocarcinoma	30/05	CI
VIVUS LLC Announces It Will Provide Telehealth to Patients Through an Enhanced 'Engage' Program in Collaboration with UpScriptHealth	22/04	CI
VIVUS LLC Announces Positive Topline Data from a Post-Marketing Study to Evaluate the Effect of QSYMIA	28/11	CI
VIVUS, Inc. Promotes Santosh T. Varghese to President VIVUS Global Pharmaceutical Development	10/23/10	CI
FDA Approves VIVUS LLC's QSYMIA® for the Treatment of Obesity in Adolescents Ages 12-17	20/22/20	CI
VIVUS, Inc. Emerged from Bankruptcy	11/20/11	CI
Revised Second Amended Reorganization Plan & Disclosure Statement Approved for VIVUS, Inc.	10/20/10	CI
First Motion for Exclusivity Period Extension Approved For VIVUS, Inc.	17/20/17	CI
Second Amended Joint Pre-Packaged Reorganization Plan Filed by VIVUS, Inc.	10/20/10	CI
First Motion for Exclusivity Period Extension Filed by VIVUS, Inc.	04/20/04	CI
Motion for Asset Sale Filed by VIVUS, Inc.	20/20/20	CI
First Amended Joint Pre-Packaged Reorganization Plan Filed by VIVUS, Inc.	18/20/18	CI
VIVUS, Inc.(NasdaqGS:VVUS) dropped from S&P TMI Index	10/20/10	CI
Motion for Joint Administration Approved for VIVUS, Inc.	10/20/10	CI
Combined Hearing for Disclosure Statement and Plan Approved for VIVUS, Inc.	10/20/10	CI
Health Care Flat As Growth Investors Seek Out Tech -- Health Care Roundup	09/20/09	DJ
VIVUS, Inc. Appoints Jill Frizzley as a Independent Director of the Company	08/20/08	CI
VIVUS, Inc. Filed for Bankruptcy	07/20/07	CI
Motion for Joint Administration Filed by VIVUS, Inc.	07/20/07	CI
Joint Pre-Packaged Reorganization Plan and Disclosure Statement Filed by VIVUS, Inc.	07/20/07	CI
VIVUS, Inc.(NasdaqGS:VVUS) dropped from Russell Microcap Index	26/20/26	CI
VIVUS, Inc.(NasdaqGS:VVUS) dropped from Russell Microcap Value Index	26/20/26	CI
VIVUS, Inc.(NasdaqGS:VVUS) dropped from Russell Microcap Growth Index	26/20/26	CI
VIVUS, Inc. Contemplates Bankruptcy	02/20/02	CI
Transcript : VIVUS, Inc., Q1 2020 Earnings Call, May 06, 2020	07/20/07

Chart VIVUS, Inc.

Duration

Period

More charts

Company Profile

VIVUS, Inc. is a biopharmaceutical company. The Company operates in the development and commercialization of therapeutic products segment. It provides over two therapies approved by the Food and Drug Association (FDA), which include Qsymia (phentermine and topiramate extended-release) for chronic weight management and STENDRA (avanafil) for erectile dysfunction (ED). The Company has completed the Phase II studies of Qsymia for the indication of Obstructive Sleep Apnea (OSA) and diabetes. Its Qsymia is available in over 40,000 certified retail pharmacies across the country. Its STENDRA is also approved by the European Commission (EC), under the name, SPEDRA, for the treatment of ED in the Europe. The United States Food and Drug Association approved a Supplemental New Drug Application (sNDA) for STENDRA. STENDRA is indicated to be taken approximately 15 minutes before sexual activity.

Sector

Pharmaceuticals

More about the company

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ELI LILLY AND COMPANY	+56.86%	815B
NOVO NORDISK A/S	+43.90%	641B
JOHNSON & JOHNSON	-6.57%	352B
MERCK & CO., INC.	+17.32%	314B
ABBVIE INC.	+9.94%	303B
ASTRAZENECA PLC	+16.08%	242B
ROCHE HOLDING AG	+2.29%	224B
NOVARTIS AG	+13.96%	218B
AMGEN INC.	+7.98%	168B

Other Pharmaceuticals